Have researchers found a biomarker to signal a more agressive form of prostate cancer?

DENVER--Researchers say they have identified a biomarker that indicates a more agressive form of prostate cancer. Fox Chase Cancer Center's chairman of radiation oncology, Alan Pollack, M.D., Ph.D., presented the findings today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

"Staging factors for prostate cancer such as PSA and the Gleason score are extremely useful in predicting prostate cancer outcome," explained Pollack. "However, new biomarkers hold promise in strengthening our ability to predict response to treatment. By identifying the more virulent forms of prostate cancer, we may be able to tailor treatment or develop therapies to target the abnormalities identified."

In the Radiation Therapy Oncology Group-sponsored study (RTOG 92-02), Pollack and his colleagues show that the overexpression of a protein called MDM2 is a strong and independent predictor that the prostate cancer will metastasize beyond the prostate gland and indicates an increased chance of death from the disease.

The study involved 469 men treated with radiation and short- and long-term androgen deprivation therapy. The median follow-up was 70.5 months. An immunohistochemical analysis was conducted on prostate tissue to determine the amount of MDM2 in the prostate cancer cells.

While other biomarkers were associated with biochemical failure, distant metastasis or overall mortality, MDM2 was consistently associated with all three outcomes. MDM2 was associated with a doubling of distant metastasis (10 to 20 percent) and a nearly 10 percent reduction in five-year survival.


Contact: Karen C. Mallet
Fox Chase Cancer Center

Page: 1

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
(Date:10/8/2015)... (PRWEB) , ... October 08, 2015 , ... Multicultural competencies ... Day, presented by Calvary Hospital. , The ninth annual event will take place from ... on Second Avenue at 34th Street in Manhattan. This location was chosen to conveniently ...
(Date:10/8/2015)... ... October 08, 2015 , ... In an increasingly complex healthcare ... to consistently deliver the highest quality of care, while exploring controversial issues impacting ... this year’s NASS meeting, the Spine division of Zimmer Biomet, a leading global ...
(Date:10/8/2015)... ... October 08, 2015 , ... Mirixa Corporation ... decade as the recognized leader in targeted patient care services, Mirixa remains dedicated ... community pharmacies available. Recent changes in the health care marketplace threaten to limit ...
(Date:10/8/2015)... White Plains, NY (PRWEB) , ... October 08, 2015 , ... ... comparison company, shows that popular, branded maintenance medications can be purchased at an 84% ... The greatest savings is 94% for the acid-blocking drug Nexium ($946.50 in the U.S. ...
(Date:10/8/2015)... ... 08, 2015 , ... Carpet One Floor & Home has just released their ... One Welcomes Your Support campaign has been raising funds to support organizations and researchers ... , Twenty-five percent of each sale will be donated to the Breast Cancer ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)...  Clariant, a world leader in specialty chemicals, has announced ... Belen, New Mexico , has achieved ISO 15378:2011 ... canisters and packets and other container-closure systems . ... second Clariant site – the first in the ... standards, following only the Clariant manufacturing facility in Romorantin, ...
(Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
(Date:10/8/2015)... -- Celtaxsys, a clinical stage drug development company focused on ... announced today the commencement of the US arm of ... compound, acebilustat, in patients with cystic fibrosis (CF). The ... the United States and European ... early 2016. This landmark clinical trial testing once-daily oral ...
Breaking Medicine Technology:
Cached News: